Active Nonsevere Polyarteritis Nodosa — When Initial Immunosuppressive Therapy Fails to Achieve Remission
Clinical Scenario
Active nonsevere polyarteritis nodosa — disease without life- or organ-threatening manifestations (e.g., mild systemic symptoms, uncomplicated cutaneous disease, mild inflammatory arthritis) — where the initial treatment course has not achieved clinical remission.
Previous Therapy — Target Not Reached
Initial treatment with a nonglucocorticoid immunosuppressive agent (azathioprine or methotrexate) combined with glucocorticoids did not achieve the required goal:
Clinical remission: absence of clinical signs or symptoms attributed to polyarteritis nodosa
Next Step — Overview
When the initial regimen fails to achieve remission, the structured protocol calls for switching to cyclophosphamide-based immunosuppression. The complete regimen — including transition steps, duration, and maintenance approach — is detailed in the full protocol.
Full criteria, sequence, and duration details are available via the protocol link below.
Treatment Goal
Clinical remission: absence of clinical signs or symptoms attributed to polyarteritis nodosa.
References
DOI: 10.1002/art.41776
- Nonsevere disease: Vasculitis without life- or organ-threatening manifestations (e.g., mild systemic symptoms, uncomplicated cutaneous disease, mild inflammatory arthritis).
- For patients with severe PAN that is refractory to treatment with glucocorticoids and nonglucocorticoid immunosuppressive agents other than cyclophosphamide, we conditionally recommend switching the nonglucocorticoid immunosuppressive agent to cyclophosphamide, over increasing glucocorticoids alone.
- Based on the effectiveness of cyclophosphamide in new-onset severe PAN, indirect evidence suggests that cyclophosphamide should be used in patients with PAN that has evolved from a nonsevere presentation to one that is severe and does not adequately respond to other immunosuppressive agents.
- Cyclophosphamide therapy should not continue indefinitely and should generally be limited to 3–6 months per course.
- For patients with newly diagnosed PAN who have achieved disease remission with cyclophosphamide, we conditionally recommend transitioning to another nonglucocorticoid immunosuppressive agent over continuing cyclophosphamide.
- Transitioning to another less toxic agent such as methotrexate or azathioprine is recommended once disease remission has been attained.
- Absence of clinical signs or symptoms attributed to PAN, on or off immunosuppressive therapy.
View source ↗